Depo-Provera Free Case Review
Lawsuits against Depo-Provera allege that the birth control injection is linked to an increased risk of meningioma — a tumor that forms in the membranes surrounding the brain and spinal cord. Plaintiffs claim Pfizer and other manufacturers failed to adequately warn patients and doctors about that risk.
More than 6,000 cases are now pending in a federal multidistrict litigation in the Northern District of Florida, with additional cases moving forward in state courts. In June 2026, Pfizer and plaintiffs’ leadership reached a global agreement in principle covering eligible claims already pending in the federal case. New cases are still being filed, and attorneys are still reviewing them.
Find out whether you may have a claim. There is no cost and no obligation.
Depo-Provera and Brain Tumors
What the research shows
- A 2024 study published in the British Medical Journal found that women who used Depo-Provera for a year or longer had roughly five and a half times the risk of developing meningioma compared to non-users.
- A 2025 study in JAMA Neurology reported an elevated risk as well, at a lower magnitude.
- In December 2025, the FDA approved updated labeling adding meningioma risk information to the warnings and patient counseling sections for Depo-Provera CI and Depo-SubQ Provera 104. Lawsuits allege that women who used the injection before that date were given no such warning.
Do I Qualify for a Depo‑Provera Lawsuit?
You may be eligible for a case review if all of the following apply:
- You received Depo-Provera, Depo-SubQ Provera, or an authorized generic (medroxyprogesterone acetate injection).
- You received at least two injections.
- You were diagnosed with a cranial or spinal meningioma, confirmed by imaging such as an MRI or CT scan, after beginning the injections.
- You are within your state’s filing deadline.
What’s Happening Now
Last updated: August 2026
- February 2025 — MDL No. 3140 is established in the U.S. District Court for the Northern District of Florida, Pensacola Division, before Judge M. Casey Rodgers. An MDL is not a class action; each plaintiff keeps an individual case.
- December 2025 — The FDA approves updated U.S. labeling addressing meningioma risk for Depo-Provera CI and Depo-SubQ Provera 104.
- Through early 2026 — Filings accelerate sharply. The court works through expert discovery, Pfizer’s federal preemption defense, and the selection of pilot cases for early trials.
- June 15, 2026 — Pfizer and plaintiffs’ leadership inform the court they have reached a global agreement in principle to resolve eligible meningioma claims pending in the MDL. The court vacates the deadlines for the first pilot trial, which had been scheduled for December 7, 2026. Pfizer states the agreement includes no admission of liability and maintains the product is safe and effective.
- July 2026 — The parties sign a master settlement agreement. Terms remain confidential: settlement tiers, medical proof requirements, individual payment amounts, and registration deadlines have not been released publicly.
- August 2026 — More than 6,000 cases are pending in the federal MDL. Additional cases continue in state courts, with the largest groups in Delaware and New York and smaller numbers in California, Illinois, Pennsylvania, Connecticut, New Mexico, and Minnesota.
Case Review
Disclaimer: This is attorney advertising. FusionByte Media LLC d/b/a FindTheFirm is not a law firm and does not provide legal advice. No attorney-client relationship is formed by submitting this form or by interacting with FindTheFirm or any participating law firm. Information on this page describes the status of ongoing litigation as of August 2026 and is subject to change; it is not a representation about your individual claim. No outcome, case acceptance, settlement, or compensation is guaranteed. Prior results do not predict future outcomes. Laws and filing deadlines vary by state. Consult a licensed attorney in your state for advice about your situation.